Sanofi now said the agreement follows completion ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...

Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration ... author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew ...

Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent ...

Almost no other industry goes as far as the phrase "defensive" as the healthcare sector, which encompasses a wide range of ...

Sanofi ( NASDAQ: SNY) has entered a share purchase agreement in relation to the sale of a 50% controlling stake in Opella, ...

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY. All trademarks mentioned in this press release are the property of the Sanofi group except for VelociSuite and Regeneron Genetics Center.

The 2023 revenues had benefited from a 30 million euros milestone payment from Boehringer Ingelheim associated with survodutide and $10 million milestone payment from Sanofi associated with ...

Sanofi SNY and partner Regeneron REGN announced that the FDA has accepted their supplemental biologics license application (sBLA) seeking approval for Dupixent for treating bullous pemphigoid (BP ...

Valeo Financial Advisors LLC decreased its holdings in Sanofi (NASDAQ:SNY – Free Report) by 62.0% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund ...

Savant Capital LLC raised its stake in Sanofi (NASDAQ:SNY – Free Report) by 24.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange ...

Sanofi and CD&R sign Opella share purchase agreementParis, February 19, 2025. Following completion of the required social and corporate ...